Increase your data's value: A value-driven semantic enrichment system to speed up scientific insight.

全球生命科学行业每年花费数十亿美元用于研究创新。这一活动产生了大量的数据，例如临床数据、组学数据，这些数据有可能产生强大的创新见解，以推动业务决策，但识别和理解数据资产可能占eResearch研究成本的80%。Eagle提出了一个数据丰富和策展平台，通过复杂的评估和优先级排序算法自动化这一关键但目前是手动的过程，这些算法将数据价值与策展工作的科学性、运营性、经济性和商业性进行权衡。Eagles平台将提高现代电子研究的有效性和效率。 MedImmune生物信息学总监Mathew Woodwark表示，科学家与数据集之间的对话是我们需要部署到RandD团队的下一波创新，因此我们可以在这个精准医学时代快速，系统地发现和验证新化合物。Eagle非常专注于解决这个问题，我们完全支持他们的产品计划。 2016年2月，Frost and Sullivan认可Eagle在向科学家描述数据价值并推动系统学习实现真正的数据驱动药物发现方面的愿景和专业知识。这种行业领导地位也将导致个性化医疗之旅中急需的转型。

The global life science industry spends billions of dollars annually on research innovation. This activity generates huge volumes of data e.g. clinical, omics with the potential to generate powerful innovation insights to drive business decisions, but dicovering and understanding data assets can account for up to 80 percent of the cost of an eResearch study. Eagle proposes a data enrichment and curation platform that automates this critical but currently manual process through sophisticated valuation and prioritisation algorithms that weigh data value against the curation effort scientific, operational, economic, business. Eagles Platform will increase the effectiveness and efficiency of modern eResearch. Mathew Woodwark, Director of Bioinformatics, MedImmune, says This conversation between the scientist and the data sets is the next wave of innovation that we need deployed to our RandD teams, so we can quickly and systematically find and validate new compounds in this Precision Medicine era. Eagle is very much focused on solving this problem and we fully support their product plans. In February 2016, Frost and Sullivan recognized Eagle for its vision and expertise in describing data value to the scientist and driving learning in the system towards true data driven drug discovery. This industry leadership will also lead to much needed transformation in the journey to personalized medicine.